By Monica Heger

This story, originally published Dec. 16, has been updated to include information about Sequenom's customers.

Two months after the launch of its non-invasive MaterniT21 test for Down syndrome, Sequenom said that a journal has accepted a study demonstrating the use of its sequencing-based approach for diagnosing trisomy 13 and 18.

Sequenom expects that the paper will be published in the first quarter of 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.